Industry analyst Evaluate has released its latest annual report on the pharmaceutical and biotechnology industries, World Preview 2019.
The report, which provides an outlook on the trends affecting the industry over the coming years, finds that prescription drug sales are forecast to reach $1.18 trillion by 2024.
Analysts suggest that growth will likely be driven by rare disease therapies and oncology drugs, which by that point are forecast to contribute $239 billion and $236 billion in sales, respectively.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze